Flibanserin approved as the 1st pharmacologic treatment option for women suffering from HSDD

August 18, 2015

Tuesday, August 18th, 2015 marked a historic day for Female Sexual Health as the US Food and Drug Administration (FDA) approved Flibanserin, the first drug of its kind in the treatment of female sexual dysfunction.

Addyi, by trade name, is a non-hormonal drug to treat Hypoactive Sexual Desire Disorder (HSDD).  HSDD is the persistent loss of desire for sexual activity that causes personal distress. Flibanserin was studied in more than 11,000 women and demonstrated a 53% improvement in desire, as measured by the Female Sexual Function Index. The study also resulted in a doubling of satisfying sexual events and a one-third reduction in sexual distress. Reported side effects include somnolence, dizziness, and nausea.

The medication is targeted for premenopausal women whose low desire is due to biological factors. It is not appropriate for women whose loss of sexual interest is due to relationship or social factors, depression, or stress.
Physicians prescribing Flibanserin and pharmacists dispensing the medication will require certification. The FDA is concerned about possible hypotension with the interaction of Flibanserin in combination with alcohol and has issued a "black box warning" to physicians and consumers. The consumption of alcohol is contraindicated in patients taking Flibanserin.

The approval of a safe and effective medication for premenopausal women suffering from low sexual desire is long overdue, and the approval of Flibanserin affords physicians an additional option in the treatment of women with low desire. ISSM would like to thank the FDA for recognizing this important, previously unmet medical need in women’s sexual health. Approving this landmark treatment will promote further research and drug development in this very important field.

For interviews of key opinion leaders or questions regarding the approval please contact:

Annamaria Giraldi,
ISSM Executive Committee 

ISSM Executive Office
P: +31 (0)75 6476372
E: secretariat@issm.info